GlassScriptPhysician profile
Dening Zhu
NPI 1760415038
$12,243.50
in general payments reported to CMS, 2019-2025
25 companies · $2,248 in 2025
The $2,248 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,577 · 2020: $728 · 2021: $2,068 · 2022: $964 · 2023: $1,000 · 2024: $2,657 · 2025: $2,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,839 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,839.06 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,053.01 | 2019-2025 | Vemlidy, Livdelzi |
| Abbvie INC. | $1,899.99 | 2019-2025 | Viberzi, Linzess |
| Novo Nordisk INC | $1,213.83 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,004.79 | 2019-2025 | Breztri, Airsupra |
| Amgen INC. | $907.17 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $405.34 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $383.54 | 2022-2024 | |
| Astellas Pharma US INC | $315.26 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $258.69 | 2025 | Auvelity, Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.08 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $192.35 | 2019-2022 | |
| Medtronic, INC. | $178.45 | 2025 | Symplicity G3 |
| Merck Sharp & Dohme LLC | $168.93 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Horizon Therapeutics Plc | $146.18 | 2023 | Tepezza, Krystexxa |
| Travere Therapeutics, INC. | $135.71 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $131.76 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $127.81 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $117.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $97.74 | 2019 | |
| Glaxosmithkline, LLC. | $93.87 | 2020-2025 | Arexvy, Shingrix |
| Allergan, INC. | $55.04 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $47.49 | 2019-2020 | |
| Seqirus USA INC | $38.90 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Baxter Healthcare | $34.47 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Sanofi Pasteur INC. | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dening Zhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.